Studies reveal potential new targeted therapies for common, hard-to-treat cancers
CHICAGO – Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). Findings from the mid- and late-stage trials suggest new ways to slow disease progression and improve survival for patients who experience relapses or resistance to available treatments.
"Cancer relapses and treatment resistance have always been among the most daunting challenges in cancer care," said ...










